Rep. Maloney Issues Opening Statement at Hearing With AbbVie CEO, Experts on Pricing Practices for Humira, Imbruvica
May 19, 2021
May 19, 2021
WASHINGTON, May 19 -- Rep. Carolyn Maloney, D-New York, chair of the House Oversight and Reform Committee, issued the following opening statement on May 18, 2021, at a hearing examining the pricing and business practices of AbbVie that sells the anti-inflammatory drug Humira and the cancer drug Imbruvica:
* * *
For more than two years, this Committee has engaged in one of the most comprehensive and in-depth investigations of pharmaceutical pricing practices ever conduct . . .
* * *
For more than two years, this Committee has engaged in one of the most comprehensive and in-depth investigations of pharmaceutical pricing practices ever conduct . . .